In the COVID-19 era, let’s keep an eye on clinical trials in Africa
dc.contributor.author | Agoro, Rafiou | |
dc.contributor.department | Medical and Molecular Genetics, School of Medicine | en_US |
dc.date.accessioned | 2020-08-17T15:29:51Z | |
dc.date.available | 2020-08-17T15:29:51Z | |
dc.date.issued | 2020-07-28 | |
dc.description.abstract | Due to the high contagiousness of COVID-19 and the lack of an effective medicine, governments and companies are urging their teams to develop new vaccine and therapy with the noble mission to protect us from COVID-19 and preserve our economic achievements. However, under the current pandemic circumstances, we cannot exclude the possibilities that some scientists violate clinical trials rules and guidelines to accelerate new vaccine and medicine development. Low-income countries, notably Africans, could be preferred as a basis for experimentations on human subjects due to the lack of stringent policies in comparison to their high-income counterparts. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Agoro, R. (2020). In the COVID-19 era, let’s keep an eye on clinical trials in Africa. Journal of Global Health, 10(2). http://www.jogh.org/documents/issue202002/jogh-10-020312.pdf | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/23623 | |
dc.language.iso | en_US | en_US |
dc.publisher | International Society of Global Health | en_US |
dc.relation.journal | Journal of Global Health | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | Publisher | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Clinical Trials | en_US |
dc.subject | Human Subjects | en_US |
dc.subject | Ethics | en_US |
dc.subject | Africa | en_US |
dc.title | In the COVID-19 era, let’s keep an eye on clinical trials in Africa | en_US |
dc.type | Article | en_US |